Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of LY333531 on Vascular and Neural Functions

This study has been completed.
Joslin Diabetes Center
Information provided by:
Chromaderm, Inc. Identifier:
First received: June 4, 2007
Last updated: July 25, 2016
Last verified: July 2016

June 4, 2007
July 25, 2016
December 2003
Not Provided
  • Improvement in endothelium-dependent vasodilation of the microcirculation of the skin and nerve axon-related reflex vasodilation. [ Time Frame: 4 weeks ]
  • Improvement in endothelium-dependent vasodilation of the brachial artery (flow mediated dilation) [ Time Frame: 4 weeks ]
  • Improvement in selective measurements of oxidative stress, endothelial activity and vascular abnormalities which will correlate with PKC activity in the peripheral monocytes. [ Time Frame: 4 weeks ]
Same as current
Complete list of historical versions of study NCT00482976 on Archive Site
Safety of ruboxistaurin [ Time Frame: 4 weeks ]
Same as current
Not Provided
Not Provided
Effect of LY333531 on Vascular and Neural Functions
The Effects of a Protein Kinase C Beta Inhibitor, LY333531, on Vascular and Neural Functions in Type 2 Diabetes Mellitus - Study B7A-MC-MBDM
To determine if protein kinase C beta plays a significant role in vascular endothelial dysfunction, small fiber neural dysfunction, and oxidative stress associated with diabetes mellitus.
32mg Ruboxistaurin; 4 week cross-over treatment.
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Diabetes Mellitus
  • Drug: Ruboxistaurin
  • Drug: Placebo
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2005
Not Provided

Inclusion Criteria:

  • Type 2 diabetes diagnosed for at least 1 mo and less than 10 yrs prior to visit 1
  • HbA1c less than 9% and fasting plasma glucose less than 260mg/dl
  • Blood pressure less than 160/100 mmHg
  • Total cholesterol less than 300 mg/dl and/or triglycerides less than 600 mg/dl

Exclusion Criteria:

  • Subjects treated with a thiazolidinedione (TZD) in 12 weeks prior to visit 1.
  • History of heart disease (MI, unstable angina, CVA, TIA, CABG, or percutaneous transluminal coronary angioplasty) w/in 6 months of visit 1 or subjects with BYHA class III or IV congestive heart failure.
  • Female subjects of child-bearing potential that are pregnant or intend to become pregnant (i.e. not practicing an acceptable method of birth control)
  • TSH greater than 1.5 times upper limit of normal at V1 or other endocrine disease.
  • ALT greater than 1.5 times upper limit of normal at V1; Serum creatinine greater than 2.0mg/dl at V1; micro-albumin greater than 300.
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
7546, B7A-MC-MBDM
Not Provided
Not Provided
Not Provided
Chromaderm, Inc.
Joslin Diabetes Center
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Chromaderm, Inc.
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP